Myriad Genetics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MYGN and other ETFs, options, and stocks.

About MYGN

Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. It develops and commercializes molecular tests that help patients and providers uncover genetic insights. 

CEO
Samraat S Raha
CEOSamraat S Raha
Employees
2,700
Employees2,700
Headquarters
Salt Lake City, Utah
HeadquartersSalt Lake City, Utah
Founded
1991
Founded1991
Employees
2,700
Employees2,700

MYGN Key Statistics

Market cap
557.16M
Market cap557.16M
Price-Earnings ratio
-4.86
Price-Earnings ratio-4.86
Dividend yield
—
Dividend yield—
Average volume
4.40M
Average volume4.40M
High today
$5.86
High today$5.86
Low today
$5.60
Low today$5.60
Open price
$5.72
Open price$5.72
Volume
2.10M
Volume2.10M
52 Week high
$8.50
52 Week high$8.50
52 Week low
$2.74
52 Week low$2.74

Stock Snapshot

With a market cap of 557.16M, Myriad Genetics(MYGN) trades at $5.86. The stock has a price-to-earnings ratio of -4.86.

During the trading session on 2026-10-24, Myriad Genetics(MYGN) shares reached a daily high of $5.86 and a low of $5.60. At a current price of $5.86, the stock is +4.6% higher than the low and still 0.0% under the high.

Trading activity shows a volume of 2.1M, compared to an average daily volume of 4.4M.

The stock's 52-week range extends from a low of $2.74 to a high of $8.50.

The stock's 52-week range extends from a low of $2.74 to a high of $8.50.

MYGN News

Investing.com 2d
Myriad Genetics presents data on cancer recurrence detection test - Investing.com

...

Myriad Genetics presents data on cancer recurrence detection test - Investing.com
TipRanks 4d
TD says Myriad Genetics prenatal divestiture proceeds ahead of expectations

After Myriad Genetics (MYGN) announced a deal to sell its Prenatal Health testing business to Labcorp (LH) for $210M in cash plus closing inventory, TD Cowen an...

Benzinga 4d
Myriad Genetics Offloads Struggling Prenatal Unit for $210 Million to Labcorp

Labcorp Holdings Inc. (NYSE:LH) has agreed to acquire the prenatal health testing business of Myriad Genetics Inc. (NASDAQ:MYGN) in an all-cash transaction valu...

Myriad Genetics Offloads Struggling Prenatal Unit for $210 Million to Labcorp

Analyst ratings

67%

of 9 ratings
Buy
11.1%
Hold
66.7%
Sell
22.2%

More MYGN News

TipRanks 4d
Myriad Genetics upgraded to Neutral from Underweight at Piper Sandler

Piper Sandler upgraded Myriad Genetics (MYGN) to Neutral from Underweight with a price target of $5, up from $2, after the company announced a deal to sell its...

TipRanks 4d
Myriad Genetics to sell Prenatal Health testing business to Labcorp

Myriad Genetics (MYGN) announced a definitive agreement for Myriad to sell its Prenatal Health testing business, which includes the Prequel, Foresight, SneakPee...

People also own

Based on the portfolios of people who own MYGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.